Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation | ||
By: GlobeNewswire - 29 May 2020 | Back to overview list |
|
LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing precision peptide cancer immunotherapies, today presented positive final data from a Phase I/II study of PolyPEPI1018, its off-the-shelf multi-peptide treatment, in microsatellite stable metastatic colorectal cancer (MSS mCRC) patients during an online poster presentation released today at the 2020 ASCO Annual Meeting. “Given the encouraging results of this clinical trial, we are moving forward with further studies of PolyPEPI1018 in conjunction with our companion diagnostic. We plan to conduct a randomized Phase II study of PolyPEPI1018 in maintenance therapy setting for first-line treatment of MSS mCRC, as well as a Phase I/II study in late-stage patients as an add-on to third-line therapy,” said Dr. Christopher Gallen, Executive Chairman of Treos Bio. “Given the boosting effect on the pre-existing immunity, there is a strong rationale for a combination of PolyPEPI1018 with checkpoint inhibitors and Treos is also exploring options for clinical trials to test such combinations.” PolyPEPI1018 is an off-the-shelf, synthetic, long peptide treatment containing immunogenic fragments of seven conserved cancer testis antigens (CTAs) frequently expressed in mCRC. PolyPEPI1018 was designed to induce polyvalent T Cell responses in a large subpopulation of CRC patients using Treos Bio’s proprietary PASCal computational tool, which identifies Personal EPItopes (PEPIs) that are likely to induce antigen-specific T Cell responses in a subject. The Phase I/II OBERTO study was an open-label, single-arm, multicenter study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of a single dose or of multiple doses of PolyPEPI1018 as an add-on to fluoropyrimidine/bevacizumab maintenance therapy in MSS mCRC patients after first-line induction chemotherapy (NCT03391232). In the trial, 11 patients with MSS mCRC were injected subcutaneously with PolyPEPI1018 just after their planned transition to maintenance therapy with fluoropyrimidine/bevacizumab following the use of first-line combo chemotherapy and bevacizumab. The first part of the study included five patients who received a single dose of the immunotherapy within 21 days of transitioning to maintenance therapy. The second part included six patients who received three doses of the immunotherapy every 12 weeks. The primary endpoint was safety. The study showed that PolyPEPI1018 was safe and well tolerated. It also produced a robust immune response against multiple tumor antigens. Immune responses induced by PolyPEPI1018 both at the peripheral and the tumor level indicate tumor response. Maintenance therapy, combined with multiple doses of PolyPEPI1018, led to objective responses and improved progression-free survival (PFS) for MSS mCRC patients. The median progression free survival (mPFS) in the multiple-dose group of 12.5 months compares favorably to results published from a recent trial conducted elsewhere in a relevant, large cohort using the same maintenance therapy but without an add-on immunotherapy (mPFS =7.4 months). The poster also included details on two patients previously determined to have unresectable disease who responded so well to the treatment with PolyPEPI1018 that each of the two patients was able to undergo curative resection. “The study showed that PolyPEPI1018 treatment both reactivates existing immune responses and induces efficient tumor-directed responses against multiple specific tumor antigens expressed in the metastases of colorectal cancer, which overrides immunological tolerance and allows clinically relevant anticancer effect,” said Mayo Clinic’s Dr. Hubbard. “Importantly, a patient’s immunological and clinical responses could be predicted using a simple buccal cheek swab test, negating the need for a tumor biopsy to identify potential responders.” About Colorectal Cancer About Treos Bio Limited Contact |
||
|
||
Copyright 2020 GlobeNewswire | Back to overview list |